D. E. I. Pyott - Mar 24, 2025 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Role
Director
Signature
By: Brett Budzinski, Attorney-in-Fact For: David E.I. Pyott
Stock symbol
ALNY
Transactions as of
Mar 24, 2025
Transactions value $
-$1,562,772
Form type
4
Date filed
3/25/2025, 04:09 PM
Previous filing
Jun 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALNY Common Stock Options Exercise $662K +7.44K +5470.59% $88.95 7.58K Mar 24, 2025 Direct F1
transaction ALNY Common Stock Sale -$2.22M -7.44K -98.2% $299.00 136 Mar 24, 2025 Direct F1
holding ALNY Common Stock 27.9K Mar 24, 2025 by Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALNY Stock Option (right to buy) Options Exercise $0 -7.44K -100% $0.00 0 Mar 24, 2025 Common Stock 7.44K $88.95 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 5, 2024. The options exercised and sold by the reporting person were due to expire on December 18, 2025.
F2 The shares of ALNY common stock were purchased by the David E I Pyott Trust, of which the reporting person is trustee.
F3 This stock option was fully vested and exercisable as of December 18, 2016.